NIH awards $12M for development of antiviral therapies

By The Science Advisory Board staff writers

November 22, 2022 -- The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health (NIH), has awarded three institutions more than $12 million for the development of antiviral therapies to treat diseases caused by viruses with pandemic potential.

The new product development contracts are part of the Antiviral Program for Pandemics (APP), which aims to accelerate the discovery, development, and manufacturing of antiviral medicines.

The following are the awardees:

  • Microbiotix for "Optimization of Broad-Spectrum Filovirus Inhibitors that Target Viral Glycoprotein"
  • Oregon Health and Science University for "Development of a Novel 2-Pyrimidone (SRI-42718) as a Potent Inhibitor of Chikungunya Virus Infection and Disease"
  • Baruch S. Blumberg Institute for "Development of an Orally Available Antiviral Drug for Yellow Fever"

The institutions will develop promising antiviral candidates from late-stage preclinical studies to investigational new drug application-enabling activities and clinical testing.

For more information about the APP, please visit the program's webpage.

Copyright © 2022

MemberID or email address:  

Forgot your password?